Beyond COVID-19: DO MS/NMO-SD patients treated with anti-CD20 therapies develop SARS-CoV2 antibodies?

Since 2019, a new coronavirus infection (COVID-19) due to an agent called SARS-CoV-2 spread rapidly worldwide. Patients with multiple sclerosis (MS) and neuromyelitis optica spectrum disorders (NMO-SD) are often treated with immunosuppressants. Beyond their effect on the risk of COVID-19 infection,...

Descripción completa

Detalles Bibliográficos
Autores principales: Maillart, Elisabeth, Papeix, Caroline, Lubetzki, Catherine, Roux, Thomas, Pourcher, Valérie, Louapre, Céline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2020
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7468278/
https://www.ncbi.nlm.nih.gov/pubmed/32916509
http://dx.doi.org/10.1016/j.msard.2020.102482
_version_ 1783578184423309312
author Maillart, Elisabeth
Papeix, Caroline
Lubetzki, Catherine
Roux, Thomas
Pourcher, Valérie
Louapre, Céline
author_facet Maillart, Elisabeth
Papeix, Caroline
Lubetzki, Catherine
Roux, Thomas
Pourcher, Valérie
Louapre, Céline
author_sort Maillart, Elisabeth
collection PubMed
description Since 2019, a new coronavirus infection (COVID-19) due to an agent called SARS-CoV-2 spread rapidly worldwide. Patients with multiple sclerosis (MS) and neuromyelitis optica spectrum disorders (NMO-SD) are often treated with immunosuppressants. Beyond their effect on the risk of COVID-19 infection, the consequences on the long-term immune response against the coronavirus remain unknown. Among 13 MS or NMOSD patients with confirmed COVID-19 included, all 5 patients treated with anti-CD20 therapies had a negative SARS-CoV-2 serology. To date, maximal precautions to prevent coronavirus infection should be maintained in MS/NMOSD patients already exposed to COVID-19 during anti-CD20 therapy.
format Online
Article
Text
id pubmed-7468278
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-74682782020-09-03 Beyond COVID-19: DO MS/NMO-SD patients treated with anti-CD20 therapies develop SARS-CoV2 antibodies? Maillart, Elisabeth Papeix, Caroline Lubetzki, Catherine Roux, Thomas Pourcher, Valérie Louapre, Céline Mult Scler Relat Disord Correspondence Since 2019, a new coronavirus infection (COVID-19) due to an agent called SARS-CoV-2 spread rapidly worldwide. Patients with multiple sclerosis (MS) and neuromyelitis optica spectrum disorders (NMO-SD) are often treated with immunosuppressants. Beyond their effect on the risk of COVID-19 infection, the consequences on the long-term immune response against the coronavirus remain unknown. Among 13 MS or NMOSD patients with confirmed COVID-19 included, all 5 patients treated with anti-CD20 therapies had a negative SARS-CoV-2 serology. To date, maximal precautions to prevent coronavirus infection should be maintained in MS/NMOSD patients already exposed to COVID-19 during anti-CD20 therapy. Elsevier B.V. 2020-11 2020-09-03 /pmc/articles/PMC7468278/ /pubmed/32916509 http://dx.doi.org/10.1016/j.msard.2020.102482 Text en © 2020 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Correspondence
Maillart, Elisabeth
Papeix, Caroline
Lubetzki, Catherine
Roux, Thomas
Pourcher, Valérie
Louapre, Céline
Beyond COVID-19: DO MS/NMO-SD patients treated with anti-CD20 therapies develop SARS-CoV2 antibodies?
title Beyond COVID-19: DO MS/NMO-SD patients treated with anti-CD20 therapies develop SARS-CoV2 antibodies?
title_full Beyond COVID-19: DO MS/NMO-SD patients treated with anti-CD20 therapies develop SARS-CoV2 antibodies?
title_fullStr Beyond COVID-19: DO MS/NMO-SD patients treated with anti-CD20 therapies develop SARS-CoV2 antibodies?
title_full_unstemmed Beyond COVID-19: DO MS/NMO-SD patients treated with anti-CD20 therapies develop SARS-CoV2 antibodies?
title_short Beyond COVID-19: DO MS/NMO-SD patients treated with anti-CD20 therapies develop SARS-CoV2 antibodies?
title_sort beyond covid-19: do ms/nmo-sd patients treated with anti-cd20 therapies develop sars-cov2 antibodies?
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7468278/
https://www.ncbi.nlm.nih.gov/pubmed/32916509
http://dx.doi.org/10.1016/j.msard.2020.102482
work_keys_str_mv AT maillartelisabeth beyondcovid19domsnmosdpatientstreatedwithanticd20therapiesdevelopsarscov2antibodies
AT papeixcaroline beyondcovid19domsnmosdpatientstreatedwithanticd20therapiesdevelopsarscov2antibodies
AT lubetzkicatherine beyondcovid19domsnmosdpatientstreatedwithanticd20therapiesdevelopsarscov2antibodies
AT rouxthomas beyondcovid19domsnmosdpatientstreatedwithanticd20therapiesdevelopsarscov2antibodies
AT pourchervalerie beyondcovid19domsnmosdpatientstreatedwithanticd20therapiesdevelopsarscov2antibodies
AT louapreceline beyondcovid19domsnmosdpatientstreatedwithanticd20therapiesdevelopsarscov2antibodies

Ejemplares similares